



BIORANKINGS

ALTERNATIVE STATISTICS CALCULATED FROM UNITED THERAPEUTICS DATA

BioRankings predicted that Inhaled Remodulin would be successful before the company's announcement

CLINICAL TRIAL

United Therapeutics launched the TRIUMPH trial of inhaled remodulin for treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class II-IV symptoms. This is a reformulation to a more efficient drug delivery from the already FDA approved injected remodulin.



A meta-analysis of Remodulin and other treatments for PAH was used to compare the TRIUMPH study to prior studies.

P value and power look-up tables were used to define a range of means and standard deviations for the likely outcomes of the TRIUMPH trial. From these tables, most reasonable outcomes would be statistically significant.

CONCLUSIONS

We concluded from our meta-analysis that TRIUMPH was highly likely to be in the green GO region (see p value look-up table above).

Three months later (November 2007) United Therapeutics reported, as we predicted, that the TRIUMPH study achieved the primary endpoint of overall 6 minute walk test improvement ($p < 0.0006$).

BIORANKINGS

William D. Shannon,
PhD

(314) 704-8725